Please find enclosed herewith Outcome of Board Meeting .

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹785.00

prior close

₹779.10

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-0.2% vs market

Pharmaceuticals peers, median of 160sector-0.1%-0.4% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.7

15m

+0.7

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.4-0.2-0.1-0.4

Next day

-7.5-1.7-5.8-0.9-6.7

-4.1-1.3-2.8-0.2-3.9

-4.5-0.7-3.8+0.3-4.8

-4.6+0.4-5.0+1.1-5.7

-3.6+0.5-4.1+0.2-3.8

-3.3+2.8-6.1+1.0-4.3

15d

-4.9+1.2-6.1-0.2-4.7

-5.9+5.3-11.2+1.7-7.6

+8.6+9.9-1.3+7.7+0.9

+4.9+13.1-8.2+8.1-3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharmaceuticals reported FY2026 audited results with standalone revenue of Rs. 6,651 crore (up 10% YoY) and consolidated revenue of Rs. 7,345 crore (up 10% YoY). Standalone PAT grew 27.3% to Rs. 640 crore while consolidated PAT rose 15.7% to Rs. 675 crore. EBITDA margins expanded to 16.82% (standalone) and 16.03% (consolidated) from 15.74% and 15.78% respectively. Exceptional items include Rs. 48.64 crore labour code impact, Rs. 18.35 crore Sikkim asset write-down, partially offset by Rs. 12.87 crore insurance recovery and Rs. 100.27 crore deferred tax asset recognition. Board recommended dividend of Rs. 12 per share (600%) vs Rs. 11 (550%) prior year. Auditors issued unmodified opinion.

Likely market impact

Strong bottom-line growth driven by margin expansion and one-time tax benefits. The Sikkim facility write-down is a concern but largely offset by insurance recovery. Dividend increase signals confidence in financial health.